Bone sialoprotein is predictive of bone metastases in resectable non-small-cell lung cancer: A retrospective case-control study

Journal of Clinical Oncology

Volumn 24, Issue 30, 2006, Pages 4818-4824

  Papotti, Mauro ^a   Kalebic, Thea ^a   Volante, Marco ^a   Chiusa, Luigi ^a   Bacillo, Elisa ^a   Cappia, Susanna ^a   Lausi, Paolo ^a   Novello, Silvia ^a   Borasio, Piero ^a   Scagliotti, Giorgio V ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BONE SIALOPROTEIN; SIALOGLYCOPROTEIN; TUMOR MARKER;

ADULT; ARTICLE; BONE METASTASIS; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; BONE TUMOR; CASE CONTROL STUDY; DISEASE COURSE; LUNG TUMOR; METABOLISM; METASTASIS; MIDDLE AGED; PATHOLOGY; PREDICTION AND FORECASTING; RETROSPECTIVE STUDY; RISK ASSESSMENT;

BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SIALOGLYCOPROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 33750622369     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2006.06.1952     Document Type: Article

References (26)

1. Roodman GD: Mechanisms of bone metastasis. N Engl J Med 350:1655-1664, 2004
2. Horak CE, Steeg PS: Metastasis gets site specific. Cancer Cell 8:93-95, 2005
3. Cho NH, Hong KP, Hong SH, et al: MMP expression profiling in recurred stage IB lung cancer. Oncogene 23:845-851, 2004
4. Karameris A, Panagou P, Tsilalis T, et al: Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas: A molecular and immunohistochemical study. Am J Respir Crit Care Med 156:1930-1936, 1997
5. Kumaki F, Matsui K, Kawai T, et al: Expression of matrix metalloproteinases in invasive pulmonary adenocarcinoma with bronchioloalveolar component and atypical adenomatous hyperplasia. Am J Pathol 59:2125-2135, 2001
6. Reichenberger F, Eickelberg O, Wyser C, et al: Distinct endobronchial expression of matrix-metalloproteinases (MMP) and their endogenous inhibitors in lung cancer. Swiss Med Wkly 131:273-279, 2001
7. Takenaka K, Ishikawa S, Kawano Y, et al: Expression of a novel matrix metalloproteinase regulator, RECK, and its clinical significance in resected non-small cell lung cancer. Eur J Cancer 40:1617-1623, 2004
8. Fedarko NS, Jain A, Karadag A, et al: Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7:4060-4066, 2001
9. Sasaki H, Yu CY, Dai M, et al: Elevated serum periostin levels in patients with bone metastases from breast but not lung cancer. Breast Cancer Res Treat 77:245-252, 2003
10. Littlewood-Evans AJ, Bilbe G, Bowler WB, et al: The osteoclast-associated protease cathepsin K is expressed in human breast carcinoma. Cancer Res 57:5386-5390, 1997
11. Brubaker KD, Vessella RL, True LD, et al: Cathepsin K mRNA and protein expression in prostate cancer progression. J Bone Miner Res 18:222-230, 2003
12. Bellahcene A, Maloujahmoum N, Fisher LW, et al: Expression of bone sialoprotein in human lung cancer. Calcif Tissue Int 61:183-188, 1997
13. Bellahcene A, Albert V, Pollina L, et al: Ectopic expression of bone sialoprotein in human thyroid cancer. Thyroid 8:637-641, 1998
14. Bellahcene A, Merville MP, Castronovo V: Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. Cancer Res 54:2823-2826, 1994
15. Bellahcene A, Menard S, Bufalino R, et al: Expression of bone sialoprotein in primary human breast cancer is associated with poor survival. Int J Cancer 69:350-353, 1996
16. Waltregny D, Bellahcene A, de Leval X, et al: Increased expression of bone sialoprotein in bone metastases compared with visceral metastases in human breast and prostate cancers. J Bone Miner Res 15:834-843, 2000
17. Waltregny D, Bellahcene A, Van Riet I, et al: Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. J Natl Cancer Inst 90:1000-1008, 1998
18. Sung V, Stubbs JT III, Fisher L, et al: Bone sialoprotein supports breast cancer cell adhesion proliferation and migration through differential usage of the alpha(v)beta3 and alpha(v)beta5 integrins. J Cell Physiol 176:482-494, 1998
19. Yoneda T, Hiraga T: Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 328:679-687, 2005
20. Karadag A, Ogbureke KU, Fedarko IMS, et al: Bone sialoprotein, matrix metalloproteinase 2, and alpha(v)beta3 integrin in osteotropic cancer cell invasion. J Natl Cancer Inst 96:956-965, 2004
21. Tye CE, Hunter GK, Goldberg HA: Identification of the type I collagen-binding domain of bone sialoprotein and characterization of the mechanism of interaction. J Biol Chem 280:13487-13492, 2005
22. Hirsh V, Tchekmedyian NS, Rosen LS, et al: Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: Analysis based on history of skeletal complications. Clin Lung Cancer 6:170-174, 2004
23. Smith MR, Kabbinavar F, Saad F, et al: Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 23:2918-2925, 2005
24. Michaelson MD, Smith MR: Bisphosphonates. for treatment and prevention of bone metastases. J Clin Oncol 23:8219-8224, 2005
25. Chaplet M, Detry C, Deroanne C, et al: Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition. Biochem J 384:591-598, 2004
26. Szabo E, Kalebic T: Chemoprevention of lung cancer: New directions. Recent Results Cancer Res 163:172-181, 2003